ZYNLONTA® (loncastuximab tesirine-lpyl) – Latex Content

Summary

- Latex is not an ingredient of ZYNLONTA. Each single-dose vial delivers 10 mg of loncastuximab tesirine-lpyl, L-histidine (2.8 mg), L-histidine monohydrochloride (4.6 mg), polysorbate 20 (0.4 mg), and sucrose (119.8 mg). After reconstitution with 2.2 mL Sterile Water for Injection, USP, the final concentration is 5 mg/mL with a pH of approximately 6.0.[1]
- The manufacturing process for ZYNLONTA is designed to prevent contamination of the product, therefore, ZYNLONTA is considered latex free.[2]
- The rubber stopper of the ZYNLONTA vials does not contain latex.[3]

Literature Search

- A PubMed biomedical literature search conducted on December 2, 2025, yielded no relevant data regarding latex content in ZYNLONTA.

Relevant Prescribing Information

Section 11: Description[1]

- ZYNLONTA (loncastuximab tesirine-lpyl) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder, which has a cake-like appearance, for intravenous infusion after reconstitution and dilution. Each single-dose vial delivers 10 mg of loncastuximab tesirine-lpyl, L-histidine (2.8 mg), L-histidine monohydrochloride (4.6 mg), polysorbate 20 (0.4 mg), and sucrose (119.8 mg). After reconstitution with 2.2 mL Sterile Water for Injection, USP, the final concentration is 5 mg/mL with a pH of approximately 6.0.

References

[1] ZYNLONTA® (loncastuximab tesirine-lpyl) for injection Prescribing Information, October 2022.
[2] Data on File, Latex Memo. ADC Therapeutics
[3] Data on File, Rubber Stopper Memo. ADC Therapeutics

ADC Therapeutics encourages all health care professionals to report any adverse events and product quality complaints to medical information at 855-690-0340. Please consult the ZYNLONTA Prescribing Information.